High sensitivity
Sensitive ctDNA detection to support assessment of recurrence or residual disease.
Tumor-informed MRD assay for solid tumors · liquid biopsy
Exceptional sensitivity. More confidence.
HPH MRD is designed to reliably detect very low amounts of circulating tumor DNA and support clinical decisions around minimal residual disease.
At a glance
Three core strengths of HPH MRD
Patient-specific assay
Tumor-informed testing based on the genetic fingerprint of the tumor.
Longitudinal monitoring
Repeated measurements can map ctDNA dynamics over time.
Foundation
What is HPH MRD?
HPH MRD is a tumor-informed ctDNA assay for assessing minimal residual disease in solid tumors, built patient-specifically from tumor and blood DNA.
1
WGS of tumor DNA from FFPE (≥30% tumor content)
2
Comparison with normal blood DNA → somatic mutations
3
Build a patient-specific assay
4
First tumor-burden measurement
5
Longitudinal monitoring
Background
HPH MRD and Haystack MRD® technology
Haystack MRD® technology builds on more than 20 years of liquid-biopsy research pioneered at Johns Hopkins University. Studies such as DYNAMIC have evaluated ctDNA as a biomarker for treatment decisions in colorectal cancer.
In the care pathway
When is HPH MRD used?
High-sensitivity MRD testing can add information at several points in the oncology pathway and does not replace individual clinical judgment.
1
Before surgery
Contextualize neoadjuvant response
2
After surgery
Assess residual disease
3
During therapy
Add response information
4
Follow-up
Earlier signals of recurrence risk
Ordering & samples
Initial testing requires tumor tissue (FFPE) and blood. Monitoring uses follow-up blood samples.